All News
Non-Serious Infection Risk with Biologics in RA
Nonserious infections (NSI) comprise the bulk of all infections seen with biologic therapies; new data from British Society for Rheumatology Biologics Register for Rheumatoid Arthritis shows that while NSI are more common than serious infections, the predictors of NSI are the same as serious infections.
Read Article
Booster Shots for Rheumatology Patients on Immunosuppressive Medications
ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive a third dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.
Read Article
RheumNow Podcast – Booster Shots for COVID (8.13.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Anakinra's Effects on COVID-19 Outcomes
Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote
Read Article
Mepolizumab Dosing in Eosinophilic Granulomatosis with Polyangiitis
A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome).
Read Article
Biologics Reduce Surgical Needs in RA
In Canada, biologic DMARDs (bDMARDs) were introduced after 2001, and since that time there have been significant reductions in hip and knee arthroplasty (THA/TKA) among patients with rheumatoid arthritis (RA), but not in patients with osteoarthritis (OA).
Read Article
Rare Risk of Serious Adverse Events After COVID Vaccination
The CDC had reported the Advisory Committee on Immunization Practices (ACIP) study of rare serious adverse events after COVID-19 vaccination and assert that the excessive morbidity and mortality from COVID-19 (and the protection afforded by vaccination) far exceeds the risk of rare safety signals
Read Article
Early MRI Sacroiliac Improvement with JAK Inhibition
The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks.
Read Article
Safety and Tolerability of Subcutaneous Methotrexate
A large, single-rheumatology center analysis of oral and subcutaneous (SC) methotrexate (MTX) use in daily clinical practice suggests that SC MTX has fewer drug discontinuations and is better tolerated compared to other DMARD therapies.
Read Article
RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)
It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.
Read Article
Delays in Joint Replacement as JIA Patients Reach Adulthood
A retrospective cohort study examined the need for joint replacement surgery in juvenile idiopathic arthritis (JIA) and showed there has been a trend to delay arthroplasty over time. The JIA category, year of implant, and presence of complications significantly affected implant survivorship.
Read Article
Rheumatic Flares Uncommon After COVID Vax
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.
Read Article
Rheumatoid Arthritis Offspring Show Normal School Performance
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
